For years, researchers have been moving towards decentralized clinical trials (DCTs), and in a matter of months, COVID-19 changed the trajectory. Clinical operations teams and investigator sites around the world rose to the challenge and worked quickly to deploy new tactics to serve their study participants. The resulting reward is that DCTs, which can be leveraged smartly to reduce participant burden and improve recruitment and retention, are now becoming more widely adopted in design considerations. But rewards bring about new risks and challenges, and DCTs create new concerns for monitoring participant safety. Dario Lirio – Senior Director, LifeSphere Clinical at ArisGlobal – analyzes the risks and rewards of DCTs.
A new position paper from noted thought leaders and the Association of Clinical Research Professionals provides the much-needed voice of the clinical trial professional.
Medable Launches Partner Network to Accelerate Innovation and Simplify Deployment of Decentralized Clinical Trials
Business, CVS Health, Data, Decentralized Clinical Trials, Direct-to-patient engagement, Health Technology, Innovation, Partnerships, R&D, Remote Site Access Technology, Software, TelemedicineMedable Inc., the leading software provider for patient-centered clinical trials, launched the Medable Partner Network – uniting a diverse ecosystem of technology, service, data, site, and direct-to-patient partners that work together to accelerate deployment of decentralized clinical trials.
Decentralized clinical trials gained a foothold in the pharmaceutical industry amidst the COVID-19 pandemic and will continue to be used once the pandemic ends, according to panelists at BIO 2020.